-
- 高橋 希人
- 万有製薬(株)
書誌事項
- タイトル別名
-
- Multi-National Clinical Trial in Circulatory Disorders
- ジュンカンキ リョウイキ ニ オケル タコクセキ リンショウ シケン
この論文をさがす
説明
As Japan becomes more integrated into the global market, pharmaceutical research and development (R&D) in Japan faces considerable challenges. While global simultaneous development including Asian countries has become a common strategy for multi-national pharmaceutical companies, Japan has been frequently set aside because of its provincial regulatory and clinical trial infrastructure. Meanwhile, many improvement programs in pharmaceutical area have been initiated in Japan. With this increased scrutiny, significant improvements in regulatory process, clinical trial costs, and site performance are anticipated over the next few years. RENAAL is the first multi-national clinical trial involving Japanese patients diabetic nephropathy associated with type II diabetes mellitus. In this article, issues which have been observed in the process of conducting multi-national clinical trial were discussed based on the experience with RENAAL. It is hoped that, as we gain more experiences in multi-national clinical trials, solutions for these issues are found in near future.<br>
収録刊行物
-
- 薬学雑誌
-
薬学雑誌 129 (2), 237-240, 2009-02-01
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206129153920
-
- NII論文ID
- 110007046102
-
- NII書誌ID
- AN00284903
-
- ISSN
- 13475231
- 00316903
-
- NDL書誌ID
- 10160726
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDLサーチ
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可